基因检测公司万基遗传（MYGN）今日盘前股价大跌6.48%，延续了昨日盘后下跌的趋势。这一显著跌幅主要源于公司最新发布的2025年第三季度财务业绩不及市场预期。
根据万基遗传发布的财报显示，公司第三季度每股亏损0.29美元，远低于分析师的预期。尽管公司报告第三季度毛利率达到69.9%，但持续的亏损状况引发了投资者的担忧。这表明公司在控制成本和提高运营效率方面可能面临挑战。
尽管财务业绩不佳，万基遗传仍然重申了其2025年的财务指引，显示公司管理层对未来业务发展保持信心。然而，市场对此反应冷淡，投资者似乎更关注当前的财务表现而非未来预期。分析人士指出，公司需要在未来几个季度中展现出明显的业绩改善，才能重新赢得投资者的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.